AstraZeneca Pharma Ind Share Price

AstraZeneca Pharma Ind Share Price

NSE: ASTRAZEN
|
Pharmaceuticals
₹ 8,050.00
+₹26.50 (0.33%)
1D
Last updated 20 Jul, 2026, 15:29 IST

AstraZeneca Pharma Ind Share Price Today

As of 20 Jul 2026, AstraZeneca Pharma Ind share price is ₹8,050.00. The stock opened at ₹8,075.00, compared to its previous close of ₹8,023.50. During today's trading session, AstraZeneca Pharma Ind share price moved in the range of ₹8,000.00 to ₹8,104.50, with an average price of ₹8,052.25 for the day. Looking at its last 52-week, the stock has touched a low of ₹7,551.50 and a high of ₹9,849.50. On the performance front, AstraZeneca Pharma Ind share price has declined by 2.38% over the last six months and is down 11.67% on a year-on-year basis.

₹8,000.00
0.33% up today
₹8,104.50
1D LOW
1D HIGH

AstraZeneca Pharma Ind Returns Calculator

Open
₹8,075.00
High
₹8,104.50
Low
₹8,000.00
Prev. close
₹8,023.50
Circuit
L
H
₹6,419.00
₹9,628.00
52-week
L
H
₹7,551.50
₹9,849.50

AstraZeneca Pharma Ind Shareholder Returns

AstraZeneca Pharma Ind Share Price History

Mkt Cap Cr
20,064.90
P/E
107.00
P/B
22.99
ROE
21.49%
D/E
0.13
ROCE
25.53%
Div. Yield
0.45%
EPS(TTM)
75.01
Turnover
2.26
EV/EBITDA
69.13
Net Margin
0.00%
Op. Margin
0.00%
ROA
9.43%
Quick Ratio
0.00
Curr. Ratio
1.80
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Astrazeneca Phar has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Astrazeneca Phar appears overvalued compared to its peers
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,63,815.0036.735.0514.85%0.5518.72%18.850.91%0.5610.90
Divis Laboratories1,92,678.0061.369.4016.19%0.0021.00%9.430.50%0.5898.19
Torrent Pharmaceuticals1,61,323.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,14,585.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Zydus Lifesciences1,13,990.0017.393.2319.69%0.3520.30%3.700.11%0.3935.38
Lupin1,11,661.0019.834.7127.01%0.0327.44%3.510.78%0.61129.18
Mankind Pharma1,02,896.001.050.1212.65%0.4212.97%5.050.05%0.5449.37
Dr. Reddy's Laboratories1,01,067.0024.972.7511.64%0.1513.65%3.320.64%0.6338.68
Aurobindo Pharma89,097.9025.442.359.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,639.3060.2610.1018.21%0.4516.70%10.190.20%0.9713.72

AstraZeneca Pharma Ind Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹1,716.29₹1,295.53₹1,002.97₹805.60
Other Income₹40.63₹34.80₹26.10₹14.76
Total Revenue₹1,756.92₹1,330.33₹1,029.07₹820.36
Total Expenses₹1,503.77₹1,127.22₹854.74₹737.32
Profit Before Tax₹156.36₹219.54₹134.10₹83.04
Tax₹40.62₹58.03₹34.81₹21.44
Profit After Tax₹115.74₹161.51₹99.29₹61.60
EPS - Basic₹46.30₹64.60₹39.70₹24.60
EPS - Diluted₹46.30₹64.60₹39.70₹24.60

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹156.36₹219.54₹134.10₹83.04
Income before WC changes₹232.77₹212.47₹129.30₹92.70
Change in Assets-₹385.82-₹95.73-₹80.09₹5.35
Change in Liabilities₹282.60-₹32.44₹49.90₹27.54
Change in WC-₹103.22-₹128.17-₹30.19₹32.89
Cash flow from Operations₹65.36₹27.87₹58.29₹100.80
Cash flow from Investing₹30.80₹21.74₹18.11₹4.74
Cash flow from Financing-₹65.59-₹44.38-₹24.48-₹9.46
Total Cash Flow₹30.57₹5.23₹51.92₹96.08
Cash (Start of the year)₹505.57₹500.34₹448.42₹352.34
Cash (End of the year)₹536.14₹505.57₹500.34₹448.42

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹175.77₹145.32₹149.40₹150.89
Current Assets₹1,342.35₹932.71₹835.47₹705.67
Total Assets₹1,518.12₹1,078.03₹984.87₹856.56
Current Liabilities₹703.00₹357.12₹383.93₹332.65
Net Current Asset₹639.35₹575.59₹451.54₹373.02
Non-Current Liabilities₹44.77₹8.99₹12.25₹12.52
Equity Capital₹770.35₹711.92₹588.69₹511.39
Total Equity & Liabilities₹1,518.12₹1,078.03₹984.87₹856.56
* All values are in INR Crore
Qty
Bid
6
8054.5
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 6
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
1
Neutral
5
Bullish
2
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
39.13
Neutral
ATR (14)
195.61
Neutral
STOCH(9,6)
24.5
Neutral
STOCH RSI (14)
0
Bullish
ADX(9)
15.55
Bullish
UO(9)
44.84
Neutral
ROC(12)
-1.87
Bearish
WillR(14)
-75.5
Neutral
Period
Simple value
Exponential vaue
5D
8165.5
8120.19
10D
8164.05
8164.91
20D
8250.15
8233.94
50D
8416.4
8341.97
100D
8427.82
8444.16

About AstraZeneca Pharma Ind

AstraZeneca Pharma Ind Share Price
ISIN
INE203A01020
Sector Market Cap
₹ 20,064.9 Cr

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

AstraZeneca Pharma Ind Financial Highlights

  • Revenue: AstraZeneca Pharma Ind reported revenue of ₹2,304.07 crore in FY26 vs ₹1,756.92 crore in FY25. It showed an increase of 31.14% on a yearly basis.
  • Operating Profit: AstraZeneca Pharma Ind reported an operating profit of ₹252.20 crore in FY26 vs ₹156.36 crore in FY25. It showed an increase of 61.29% on a year-on-year basis.
  • Net Profit: AstraZeneca Pharma Ind reported a net profit of ₹187.52 crore in FY26 vs ₹115.74 crore in FY25. It showed an increase of 62.02% on a yearly basis.

AstraZeneca Pharma Ind Quarterly Result Highlights

  • AstraZeneca Pharma Ind reported revenue of ₹584.56 crore in Mar 2026, compared with ₹616.70 crore in Dec 2025, representing a decrease of 5.21% on a quarter-on-quarter (QoQ) basis.
  • AstraZeneca Pharma Ind reported an operating profit of ₹58.14 crore in Mar 2026, compared with ₹46.54 crore in Dec 2025, representing an increase of 24.92% on a quarter-on-quarter (QoQ) basis.
  • AstraZeneca Pharma Ind reported a profit of ₹44.88 crore in Mar 2026, compared with ₹32.59 crore in Dec 2025, reflecting an increase of 37.71% on a QoQ basis.
  • The earnings per share (EPS) of AstraZeneca Pharma Ind stood at ₹46.30 during Mar 2026.
Know more
Promoters
75.00%
FII
2.78%
Other DII
0.13%
Retail and other
16.42%
Mutual funds
5.66%
Foreign institutions - FII
Compare against other stocks
AstraZeneca Pharma Ind Share Price
AstraZeneca Pharma Ind
Pharmaceuticals
Add Stock
Add Another

FAQs on AstraZeneca Pharma Ind Share Price